|Day Low/High||104.02 / 109.00|
|52 Wk Low/High||29.51 / 94.01|
S&P closes near the lows of the day as momentum names get hit.
Tesaro (TSRO) stock closed higher in Monday's trading session after Pfizer (PFE) agreed to pay $14 billion for Medivation (MDVN).
Shareholders of the oncology drug maker ought to be satisfied with the auction's conclusion.
Overall, this is still a good environment for stock picking.
Acquiring Medivation will strengthen Pfizer's oncology franchise, which has lost ground in recent years to some Big Pharma competitors.
Bears continue to have a tough time gaining traction.
There is hesitancy to chase, especially with the FOMC rate decision this afternoon.
Cramer says don't buy Tesaro but do buy Cirrus Logic.
Cramer says discipline is needed to start trimming positions and taking profits.
Keep in mind that strong action like this tends to create underlying support.
In most cases ovarian cancer recurs within two years after chemotherapy, but the Tesaro (TSRO) drug stops that, Dr. Marc Siegel explained on Fox Business today.
Tesaro (TSRO) stock is falling this morning despite the success of its cancer drug trial after it announced an offering of $300 million worth of common stock to the public.
Here are Thursday's top research calls, including upgrades for General Mills, Priceline, PulteGroup and Yelp.